Literature DB >> 16510204

Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases.

Natàlia Ferré1, Judit Marsillach, Jordi Camps, Bharti Mackness, Michael Mackness, Francesc Riu, Blai Coll, Mònica Tous, Jorge Joven.   

Abstract

BACKGROUND/AIMS: We previously reported that paraoxonase-1 activity measurement may be useful for the evaluation of liver diseases. Because oxidative stress plays a role in liver apoptosis, and lipid peroxides are hydrolyzed by paraoxonase-1, we have extended our studies to explore the relationships between this enzyme and oxidative stress, fibrosis and apoptosis.
METHODS: We measured paraoxonase-1 activity and concentration, soluble FAS concentration, serum fibrosis markers, and total peroxides in a group of patients with minimal hepatic changes (n=25), chronic hepatitis (n=51), or liver cirrhosis (n=17). We also measured the Knodell activity index in liver biopsies and performed FAS and PON1 immunostaining.
RESULTS: Patients with liver diseases showed an increase in soluble FAS, fibrosis markers and paraoxonase-1 concentrations, as well as a decrease in PON1 activity. Paroxonase-1 activity and concentration were correlated with soluble FAS (r=-0.43, P<0.001 and r=0.27, P=0.007, respectively). Paraoxonase-1 concentration showed a significant inverse association with FAS immunostaining (P=0.013) and a direct association with PON1 immunostaining (P<0.001).
CONCLUSIONS: These results suggest an active role of PON1 in the regulation of oxidative stress, fibrosis and hepatic cell apoptosis in chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510204     DOI: 10.1016/j.jhep.2005.12.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  26 in total

1.  2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.

Authors:  Marika Cordaro; Rosalba Siracusa; Rosalia Crupi; Daniela Impellizzeri; Alessio Filippo Peritore; Ramona D'Amico; Enrico Gugliandolo; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

2.  Protandim does not influence alveolar epithelial permeability or intrapulmonary oxidative stress in human subjects with alcohol use disorders.

Authors:  Ellen L Burnham; Joe M McCord; Swapan Bose; Lou Ann S Brown; Robert House; Marc Moss; Jeanette Gaydos
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-20       Impact factor: 5.464

3.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

4.  Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection.

Authors:  Fazilet Duygu; Suda Tekin Koruk; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

5.  Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.

Authors:  Shu Zhang; Kai Jiang; Qinle Zhang; Kun Guo; Yinkun Liu
Journal:  Glycoconj J       Date:  2015-02-22       Impact factor: 2.916

6.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

7.  Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.

Authors:  Eline H van den Berg; Eke G Gruppen; Richard W James; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2018-11-19       Impact factor: 5.922

8.  Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment.

Authors:  Judit Marsillach; Gerard Aragonès; Bharti Mackness; Michael Mackness; Anna Rull; Raúl Beltrán-Debón; Juan Pedro-Botet; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-05-14       Impact factor: 3.876

9.  Paraoxonase-1 status in patients with hereditary hemochromatosis.

Authors:  Nicola Martinelli; Anabel García-Heredia; Helena Roca; Núria Aranda; Victoria Arija; Bharti Mackness; Michael Mackness; Fabiana Busti; Gerard Aragonès; Juan Pedro-Botet; Federica Pedica; Ivana Cataldo; Judit Marsillach; Jorge Joven; Domenico Girelli; Jordi Camps
Journal:  J Lipid Res       Date:  2013-03-06       Impact factor: 5.922

10.  Serum lactonase and arylesterase activities in alcoholic hepatitis and hepatitis B.

Authors:  Mukund Ramchandra Mogarekar; Swati Jitendra Talekar
Journal:  Indian J Gastroenterol       Date:  2013-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.